http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Suh Susie (검색결과 5 건)
- 무료
- 기관 내 무료
- 유료
-
점안제로 오인하여 사용한 순간접착제에 의한 안손상의 임상양상 및 예방법
석수지,이승우,서억수,김호창,Susie Soek,Seung Woo Lee,Euk Su Suh,Ho Chang Kim 대한안과학회 2010 대한안과학회지 Vol.51 No.10
Purpose: To investigate the clinical features and prevention of ocular injuries associated with the mistaken use of superglue as eyedrops. Methods: Medical records of 13 patients with ocular superglue injury who visited our hospital from January 1, 2002 to December 31, 2004 were analyzed. The clinical features of ocular superglue injury and causes of using superglue instead of eyedrops for each patient were analyzed. Results: The present study involved 15 eyes of 13 patients, including seven men (53.8%) and six women (46.2%), ranging from 6 to 72 years of age, with a mean age of 38.4 years. Ocular superglue injuries were corneal abrasion in all patients. The bonding of eyelids (eight cases, 61.5%) and eyelashes (two cases, 15.4%) were identified. Ocular injuries were treated conservatively and resolved without complications. The major cause of mistaken use of superglue was similarly packaged eye drops (11 cases, 84.6%). Other causes included poor eyesight (one case) and unsupervised children (one case). Conclusions: The availability of eyedrops in various ocular diseases has recently increased, and superglue is found in many households, wherefore incidence of ocular superglue injuries can increase. Therefore, modifying the design of superglue bottles and providing proper education for patients to prevent ocular superglue injury is important. J Korean Ophthalmol Soc 2010;51(10):1398-1402
-
Genome editing in the treatment of ocular diseases
Choi Elliot H.,Suh Susie,Sears Avery E.,Hołubowicz Rafał,Kedhar Sanjay R.,Browne Andrew W.,Palczewski Krzysztof 생화학분자생물학회 2023 Experimental and molecular medicine Vol.55 No.-
Genome-editing technologies have ushered in a new era in gene therapy, providing novel therapeutic strategies for a wide range of diseases, including both genetic and nongenetic ocular diseases. These technologies offer new hope for patients suffering from previously untreatable conditions. The unique anatomical and physiological features of the eye, including its immune-privileged status, size, and compartmentalized structure, provide an optimal environment for the application of these cutting-edge technologies. Moreover, the development of various delivery methods has facilitated the efficient and targeted administration of genome engineering tools designed to correct specific ocular tissues. Additionally, advancements in noninvasive ocular imaging techniques and electroretinography have enabled real-time monitoring of therapeutic efficacy and safety. Herein, we discuss the discovery and development of genome-editing technologies, their application to ocular diseases from the anterior segment to the posterior segment, current limitations encountered in translating these technologies into clinical practice, and ongoing research endeavors aimed at overcoming these challenges.
-
박혜진,박지연,서태석,이정우,김미화,오영택,전미선,노오규,Susie Suh 한국물리학회 2013 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.62 No.11
The dosimetric effects of variable grid size and angular increment were systematically evaluated in the measured dose distributions of dynamic conformal arc therapy (DCAT) for lung stereotactic body radiation therapy (SBRT). Dose variations with different grid sizes (2, 3, and 4 mm) and angular increments (2, 4, 6, and 10◦) for spherical planning target volumes (PTVs) were verified in a thorax phantom by using EBT2 films. Although the doses for identical PTVs were predicted for the different grid sizes, the dose discrepancy was evaluated using one measured dose distribution with the gamma tool because the beam was delivered in the same set-up for DCAT. The dosimetric effect of the angular increment was verified by comparing the measured dose area histograms of organs at risk (OARs) at each angular increment. When the difference in the OAR doses is higher than the uncertainty of the film dosimetry, the error is regarded as the angular increment effect in discretely calculated doses. In the results, even when a 2-mm grid size was used with an elaborate dose calculation, 4-mm grid size led to a higher gamma pass ratio due to underdosage, a steep-dose descent gradient, and lower estimated PTV doses caused by the smoothing effect in the calculated dose distribution. An undulating dose distribution and a difference in the maximum contralateral lung dose of up to 14% were observed in dose calculation using a 10◦ angular increment. The DCAT can be effectively applied for an approximately spherical PTV in a relatively uniform geometry,which is less affected by inhomogeneous materials and differences in the beam path length.
-
Heo, Chaejeong,Lee, Si Young,Jo, Areum,Jung, Susie,Suh, Minah,Lee, Young Hee American Chemical Society 2013 ACS NANO Vol.7 No.6
<P>Enhancing cerebral blood volume (CBV) of a targeted area without causing side effects is a primary strategy for treating cerebral hypoperfusion. Here, we report a new nonpharmaceutical and nonvascular surgical method to increase CBV. A flexible, transparent, and skin-like biocompatible graphene electrical field stimulator was placed directly onto the cortical brain, and a noncontact electric field was applied at a specific local blood vessel. Effective CBV increases in the blood vessels of mouse brains were directly observed from <I>in vivo</I> optical recordings of intrinsic signal imaging. The CBV was significantly increased in arteries of the stimulated area, but neither tissue damage nor unnecessary neuronal activation was observed. No transient hypoxia was observed. This technique provides a new method to treat cerebral blood circulation deficiencies at local vessels and can be applied to brain regeneration and rehabilitation.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/ancac3/2013/ancac3.2013.7.issue-6/nn305884w/production/images/medium/nn-2012-05884w_0008.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/nn305884w'>ACS Electronic Supporting Info</A></P>
-
Kim, Jung Kuk,Seo, Young-Kyo,Park, Sehoon,Park, Soo-Ah,Lim, Seyoung,Lee, Susie,Kwon, Ohman,Seo, Jeong Kon,Choi, Ung-Kyu,Ryu, Sung Ho,Suh, Pann-Ghill National Research Council of Canada = Conseil nati 2015 Biochemistry and cell biology Vol.93 No.3
<P> Mast cells are responsible for IgE-mediated allergic responses through the secretion of various inflammatory cytokines and mediators. Therefore, the pharmacological regulation of mast cell activation is an important goal in the development of novel anti-allergic drugs. In this study, we found that spiraeoside (SP) inhibits mast cell activation and allergic responses in vivo. SP dose-dependently inhibited the degranulation induced by IgE-antigen (Ag) stimulation in RBL-2H3 mast cells without cytotoxic effects. At the molecular level, SP reduced the Ag-induced phosphorylation and subsequent activation of phospholipase C-γ2 (PLC-γ2). Moreover, SP inhibited the phosphorylation of spleen tyrosine kinase (Syk), linker for activation of T cells (LAT), and downstream MAPKs, such as ERK1/2, p38, and JNK, eventually attenuating expression of TNF-α and IL-4. Finally, we found that SP significantly inhibited IgE-mediated passive cutaneous anaphylaxis (PCA) in mice. Taken together, our results strongly suggest that SP suppresses IgE-mediated mast cell activation and allergic responses by inhibiting Lyn-induced PLC-γ2/MAPK signaling in mast cells. </P>
KCI
스콜라연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
